drugset / Trial / NCT04778644

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

NCT04778644 ↗

Phase 1/2 Unknown 20 enrolled Hartford Hospital Yale University · collab
RandomizedCrossoverQuadruple-blindOther

Summary

Cannabidiol (CBD) is another cannabis plant derivative for which, like THC, there has been extensive research. Unlike THC however, CBD is non-intoxicating and non-psychedelic. CBD has antipsychotic effects. Logically, if CBD opposes THC effects, it may be a potential antipsychotic treatment. The purpose of this pilot research is to show target engagement of the hippocampus with the study drug (CBD versus placebo) in patients who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychosis compared to healthy controls.

Timeline

Start
2021-12-15
Primary completion
2025-12-15
Completion
2025-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CBD Unknown 600 mg Oral

Indications

No indication recorded.